BioPharma Dive December 15, 2023
Welireg, which Merck got through a 2019 buyout, can now be used to treat an advanced form of kidney cancer, adding to an earlier clearance in a rare genetic disease.
Dive Brief:
- The Food and Drug Administration on Thursday broadened use of a drug Merck & Co. acquired in a $1 billion buyout four years ago, clearing Welireg for use in people whose kidney tumors have progressed following treatment with two other types of medicines.
- Approval was based on a trial that compared Welireg to an older therapy called everolimus. Merck’s drug reduced the risk of cancer progression or death by 25% compared with everolimus and shrank or eliminated tumors in 22% of people who received it. Welireg...
Today's Sponsors
Today's Sponsor